Method of treating retinal and vitreous hemorrhage
SUBSTANCE: treating retinal and/or vitreous hemorrhages is ensured by a session of subcutaneous administration of Histochrom 0.5 ml into a mastoid bone, Echinacea compositum 1.0 ml into a temporal fossa, Gemase 2500-5000 IU parabulbary dissolved in Lymphomyosot 0.5-1.0 ml. The therapeutic course is 10-15 sessions, either daily or every second day.
EFFECT: faster resolution of the intraocular hemorrhages, prevention of retinal injuries by toxic decay products, higher visual acuity.
The invention relates to medicine, namely to ophthalmology, and is intended for the treatment of hemorrhages in the retina and the vitreous body.
One of the causes of low vision, blindness, and disability among older persons, but in the younger age groups are vascular diseases of the eye. One of the manifestations of vascular disorders are bleeding in the retina and in the vitreous body, causing a decrease in visual acuity, retinal detachment, secondary glaucoma, retinal degeneration, etc.
Currently, in the treatment of vascular diseases of the eye are widely used vasodilator drugs, vitamins, bio-stimulants, antioxidants, angioprotectors. However, despite the wide selection of medicines, the task of creating a new, effective, affordable with no side effects of medicines remains relevant.
There is a method of treatment of hemorrhages in the vitreous body (hemophthalmus by daily intravenous infusion of a solution gemodeza in combination with complex medicines: parabulbar injection of dexamethasone, etamzilat sodium, magnetophoresis with collision, injections tohoto under the skin of the temple (EN 2231338).
The known method of conservative treatment of the case of using hypertonic solutions: chlorine is Yes sodium, glucose, mannitol, an osmotic pressure which is higher than in blood plasma (Gundorov R.A. and other eye Injuries, - M.: Medicine, 1986, s-286).
However, low-molecular hypertonic solutions increase the osmotic component of the pressure of blood plasma and is removed in the bloodstream liquid fraction streamed into the vitreous body of blood, effective only during the infusion, as quickly removed from the vascular system due to induced osmotic diuresis.
There is a method of treatment of the case, including the conduct of daily intravenous infusions of balanced on the main electrolytes in the blood plasma solution gemodeza (EN 2148972, 20.05.2000).
There is a method of treatment of hemorrhage of the retina with the help of homeopathic remedies - Phosphorus, Arnica, Lachesis (T.A. Granikova. Short course on homeotherapy. L., 1991, s). However, the method is not effective enough, as it has a therapeutic effect on all stages of the disease.
The closest analogue of the proposed method is a method of the same purposes, including the use of complex homeopathic remedies containing Phosphorus, Arnica, Lachesis, Apis, Nux vomica and Carbo vegetabilis (EN 2242237, 20.12.2004).
The task of the invention is to develop a new homeopathic method of treatment of hemorrhages in the retina and the vitreous body.
Technical re is the query result of the proposed method is accelerated resorption of intraocular hemorrhages, warning damage to the retina toxic products of decomposition with increasing visual acuity.
Technical result is achieved due to the combined effect with the use of drugs: injected subcutaneously in the region of the mastoid process of the drug Histogram, in the region of the temporal fossa - drug "Echinacea compositum"entered parabulbarno drug "Gamesa"diluted the drug "under given circumstances".
The basis of a combined treatment of said pathology is thrombolytic therapy, which aims at dissolving the resulting hemorrhage and restoration of the local blood flow. One of the most effective fibrinolitikov for local use in ophthalmology believe the drug "Hamasu". Having fibrinolytic and disaggregated action, "Gamesa" promotes lizirovania venous thrombus, rapid recovery of blood flow in the affected Vienna and resorption of hemorrhages in the eye fundus. The drug is used in the form of parabulbar injection of 5,000 IU 1 time a day for 10 days (Neroev CENTURIES, Lysenko V.S. Treatment of hemorrhagic syndrome in vascular diseases of the retina. // Manual for doctors. M., 2004. P.1-10).
Drugs under given circumstances" and "Echinacea compositum" are homotoxicological means, produced by the German firm "Heel" are included in the register of medicines, approved for use in the Russian Federation.
According to the literature, between the cytoplasmic membrane of the microvilli of the epithelial cells of the retina and the membrane of the photoreceptor is detected by the slit-like space formed interphotoreceptor matrix secreted by cells of the pigment epithelium and consists of chondroitin sulphate (60%), sialic (25%) and hyaluronic (15%) acids (Sh. Acharya, I.R. Rodriguez, E.F. Moreira et al. SPACR, a Novel Interphotoreceptor Matrix Glycoprotein in Human Retina That Interacts with Hyaluronan. // J. Biological Chemistry, 1998. N.273 (47). P.31599-31606). Violation of the structural organization of the matrix is the reason for the development of various types of retinal degeneration. Zhukov, S., Shchuko A.G., Malyshev V.V. Pigment abiotrophy of the retina. M: GEOTAR-Media, 2010, 112 S.
Under given circumstances - the drug, the point of application of which is the extracellular matrix. Under given circumstances is increased its drainage function. Its use allows not only to lyse hemorrhage, but also to contribute to the elimination of the products of lysis of the retina. In the matrix, the drug activates the end products of glycation, which contributes to the activation of eliminating degradation products of the extracellular matrix.
The drug "under given circumstances" is the product of water-based, because the drug "Gamesa", according to the instructions, diluted in water use under given circumstances as a solvent is not contradictory, the cheat instructions. Thus, when recommended for introduction into parabulbar space the volume of liquid you can enter two drugs that act on different pathogenic components of the pathological process in hemorrhages in the retina and the vitreous body.
The drug Echinacea compositum has a multi-component composition and has Antihemorrhagics, immunostimulatory, anti-inflammatory, analgesic action General therapy 2010-2011. The catalog of preparations of firm "heel". ZAO Arabia, 2012.
The drug Histogram" refers to the antioxidant drugs, it stabilizes the cell membrane, is the interceptor free of reactive oxygen species, free radicals, has chemoresistance, retinoprotective effects (Egorov E.A., Alekhine, VA, Volobueva T.M., Fedoseev S.A., Mishchenko, NP, Koltsova E. New mountianside "Histogram" in the clinic of eye diseases. To oftalmol. 1999; 2:34-35).
The complex of the drugs used simultaneously to provide action on the resolution and prevention of further bleeding, and excretion of toxic degradation products, as well as to the stimulation of local immunity.
Clinically this is manifested in resorption, hemorrhage, reducing edema syndrome and, consequently, to improve the sharpness of SREN what I what is the ultimate goal of therapy.
The method is as follows. The surface of the skin in the injection process 70% alcohol. For the introduction of drugs selected the following areas of regional blood flow: insulin syringe subcutaneously in the region of the mastoid process impose drug Histogram in a volume of 0.5 ml, in the region of the temporal fossa drug Echinacea compositum" in a volume of 1.0 ml, parabulbarno drug "Gamesa" 2500-5000 ME running to the drug "under given circumstances", in the amount of 0.5-1.0 ml, the rate of 10-15 sessions every day or two.
Patient X. 36 years old, was admitted to the Hematology unit 20.08.12 with a diagnosis of Acute leukemia. T-lymphoblastic option.
Upon examination by an ophthalmologist: complaints about sudden decreased vision in the left eye during the 16 days, the presence of a Central scotoma. Visual acuity of the right eye and 1.0; the left - 0,1 not also corrected. The position of the eyeballs correct movement in full, convergence in norm. Anterior segment without features. The fundus of the right eye: optic nerve disc pale pink, clear boundaries, the retinal vessels - twisted sharply, artery uneven caliber, with faint blood flow, the veins are tortuous, irregular caliber, full, extended, macular region and the periphery without focal changes.
The fundus of the left eye: optic nerve disc pale pink, borders Schusev the us, excavation saved on the upper pole Azkaban hemorrhage with indistinct contours, tortuous retinal vessels, neravnomernomu caliber with faint blood flow, the veins are tortuous, irregular caliber, full, extended, along the vascular arcades retinal hemorrhages with indistinct contours, variegated, swelling of the macular area, hemorrhage in the macula with clear contours in the area of the foveolar pit.
Was diagnosed with OS - acute circulatory disturbance of the retina, incomplete thrombosis of the CCS; OU - angiopathy of the retina.
After consultation with the attending physician was treated under the proposed method, including local injection of drugs Gamesa ME 5000 dissolved on the under given circumstances 1,0 parabulbarno; Echinacea compositum of 1.0 in the temporal region and Histogram 0.5 in the region of the mastoid process to the left. Eye care was only complementary to the treatment of the underlying disease and was conducted during therapy Protocol Hoeltzer 99.
RESULTS. On the 10th day from the start of treatment ophthalmoscopically noted a significant decrease in edema of the macula. Visual acuity of 0.1. By this time it was done 4 sessions combined injection. After 2 weeks from the start of treatment after 6 sessions of injections, the patient noted a subjective depression of the Central scotomas. Visual acuity of 0.1. A-day treatment after 9 sessions marked improvement of visual acuity to 0.4. Altogether there were 15 sessions of injection treatment. Ophthalmological status after treatment of the following: visual Acuity of the right eye and 1.0; the left eye was 0.9 (not also corrected). In dynamics, the patient noted significant improvement of visual functions. The fundus of the left eye: optic nerve disc pale pink, clear boundaries, hemorrhage along the vascular arcades and disk area resorbed. In the field of foveolar pit hearth red color with clear contours. There macular reflex, ophthalmoscopically visible swelling there. The tortuous retinal vessels, uneven caliber arteries narrowed veins full-blooded, the ratio A:B=1:2.
The improvement from the side view correlated with the improvement of the General condition of the patient. When viewed through 3-month visual acuity of the right eye and 1.0; the left eye is 1.0. Anterior segment of both eyes without pathology. Optical transparent environment. The fundus of the eye is almost the same in both eyes. The optic nerve disc pale pink, clear contours, the retinal vessels narrow, hypotonie, tortuous, vascular figure depleted. Retin-a pink, shiny, macular reflex pronounced edema no. In comparison with the right eye, the macula in the left eye has a more intense color. When viewed through 6 months visual acuity of the right eye and 1.0; the left eye is 1.0. Anterior segment without pathology. The fundus of the eye di is to: pale pink with clear boundaries; the retinal vessels tortuous, constricted, A:V=1:2; macular area: reflex saved, foveola bright red color with clear contours.
Produced study fundescola pictures is determined by the redistribution of pigment yellow spots on the EAST - scanning - the accumulation of pigment in the field of foveolar pit compared to the right eye. Thus, a comprehensive treatment of the method described above allowed us to achieve resorption of hemorrhages, resolution of macular edema and recovery of visual acuity of the affected eye.
Patience So, 42 years old, came with complaints of blurred vision in the left eye, the feeling of fog over the left eye in the last 10 days. Noted paroxysmal headache about 2 weeks ago, which was bound by the emotional stress. Visual acuity of the right eye and 1.0 in the left eye - 1,0 IOP OD 20 mm Maklakova, OS 19 mm Maklakova. Anterior segment of both eyes without features. The fundus of the right eye: optic nerve disc pale pink, clear contours, tortuous retinal vessels, arteries narrowed stopovers tortuous veins full-blooded, normal caliber, tense, A:B=1:2, the macula without features, reflex saved. The fundus of the left eye: optic nerve disc pale pink, clear contours, tortuous retinal vessels, arteries narrowed stopovers tortuous, Vienna polnoc is Aries, normal caliber, tense, along vernaison vein swelling of the retina, soft vatoobraznye exudate white, variegated hemorrhage,/temporal Vienna uneven caliber with faint blood flow in/temporal artery narrowed sharply in places spacerowa, in the macula without pathological changes, somewhat reduced macular reflex. The field of vision of the right eye is in the normal range, the left eye was recorded loss verkhnevizeiskogo sector, not affecting the Central area up to 20 degrees. The patient was treated in a specified way: Gamesa ME 5000 dissolved on the under given circumstances 1,0 p/b; Echinacea compositum of 1.0 in the temporal region and Histogram 0.5 in the region of the mastoid process, was injected drugs with 2 sides, because of the phenomenon angiopathy were expressed with 2 sides. The sessions were held through the day, No. 10 of treatment. Upon completion of the course: the visual Acuity of the right eye and 1.0 in the left eye to 1.0. Anterior segment of both eyes without features. The fundus of the right eye: optic nerve disc pale pink, clear contours, tortuous retinal vessels, arteries are narrow, tortuous veins moderately full, normal caliber, A:B=1:2, the macula without features, reflex saved. The fundus of the left eye: optic nerve disc pale pink, clear contours, tortuous retinal vessels, arteries narrowed saved corkscrew tortuous in the field top the temporal arcades, infiltrates, hemorrhage resorbed, swelling regressed, Vienna full, normal caliber, A:B=1:2-3.
Field of view is fully recovered to the limits of physiological norm.
Thus, a comprehensive treatment of the method described above has resulted in resorption of hemorrhages and exudates, recovery of visual fields and visual functions of the affected eye.
Patience M, 59 years old was admitted to the neurology Department with a diagnosis of Diabetic encephalopathy. Moderate vestibular-atactic Sandra, angina 2 FC. Arterial hypertension 2 tbsp., risk 4. Diffuse-nodular euthyroid goiter 1 tbsp. Sugar diabetes type 2, insulin dependent, severe, subcompensated. The state after baloney angioplasty with stenting anterior descending, circumflex, diagonal, right coronary artery from 2006
During the examination the ophthalmologist noted sudden loss of vision in his right eye within the last 10 days.
OD: O/SP (b/C): account of the fingers of a person sph: n/a
OS: On/SP (b/C): 0,5 sph: - 1,0 O/WR (from/to): 0,7.
Anterior segment of both eyes without features. When biomicroscopy: OD total hemophthalmus. The fundus of the eye - the Central area is not ophthalmoscopically, on the periphery of the multiple different-sized hemorrhages. OS: in the vitreous body floating pomot is possible. The fundus of the eye disc: pale pink with clear boundaries in the area of the optic nerve disc growth of newly formed blood vessels, proliferation in the vitreous body; vessels: the tortuous, artery moderately constricted veins full of uneven caliber, different-sized hemorrhages, deposition of hard exudates throughout the retina. Diagnosis: Diabetic proliferative angiopathy OS. Total hemophthalmus OD. The patient was treated under the proposed method daily right: Gamesa ME 5000 dissolved on the under given circumstances 1,0 p/b; Echinacea compositum of 1.0 in the temporal region and Histogram 0.5 in the region of the mastoid process. After 2 days, the patient had depression fog in front of the right eye. Visual acuity accounted for 0.08. 6 days after the 4 sessions of combined treatment visual acuity OD=0,2. The fundus was not ophthalmoscopically. 11 days after 8 sessions of combined treatment the visual acuity of the right eye was 0.5 n/a, the left eye of 0.5 sph(-)1,0=0,7. Treatment was done 8 sessions on the proposed method. The treatment was not continued due to discharge of the patient from hospital. This case demonstrates the rapid resolution total hemophthalmos with improvement of visual acuity in the complex therapy on the proposed method. The patient was assigned to outpatient treatment.
Thus, the proposed pic is b allows to achieve the cupping process and improve visual acuity in patients with severe eye pathology.
A method of treatment of hemorrhages in the retina and vitreous body, wherein subcutaneously in the region of the mastoid process impose drug Histogram in a volume of 0.5 ml, in the region of the temporal fossa drug Echinacea compositum in a volume of 1.0 ml, parabulbarno - drug "Gamesa" 2500-5000 ME running to the drug "under given circumstances", in the amount of 0.5-1.0 ml, the rate of 10-15 sessions every day or two.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, to preparations for the treatment and prevention of eye diseases, and may be used in visual impairment, development and progression of eye diseases, as well as for the prevention and maintenance therapy of oxular diseases. Substance of the invention consists in the fact that a therapeutic eye balsam is characterised by the fact that it contains the ingredients in ratio in grams per 100 g of the therapeutic eye balsam of the following formulation: Siberian fir extract - 48.540 g, 5% propolis extract - 10.000 g, 0.9% physiological saline - 38.540 g, neoselen (food supplement) - 0.971 g, vitamin B2 - 0.007 g, citric acid - 0.971 g, ascorbic acid - 0.971 g that promotes achieving the declared technical effect ensured by the given proportions. The presented balsam enables the higher clinical effectiveness in all the forms of ocular pathologies, provides the anti-inflammatory effect on the eye mucosa and cornea, as well as delivers a good result in the post-traumatic and post-operative treatment.
EFFECT: therapeutic eye balsam containing the natural ingredients in certain proportions provides the integrated therapeutic effect on the visual organs and has found use in a great number of grateful patients.
FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to a pharmaceutical composition and methods of using it in treating insufficient eye lubrication, related symptoms or adverse conditions related to insufficient eye lubrication. The pharmaceutical composition contains human PRG4, its wetting fragment, a homologue or an isoform suspended in ophthalmologically acceptable balanced saline. The pharmaceutical composition can also contain one or more ophthalmologically acceptable agents specified in a group consisting of a sedative, an excipient, a binding agent, a vasoconstrictor, an emollient, sodium hyaluronate, hyaluronic acid and surface active phospholipids in a pharmaceutically acceptable carrier for topical use.
EFFECT: group of inventions provides treating the diseases related to impaired corneal and conjunctival wetting.
15 cl, 10 dwg, 3 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: what is presented is a method for the suppression of physiological disorders related to abnormal angiogenesis, specified in retinopathy, diabetic retinopathy, macular degeneration, retinopathy of prematurity, age-related macular degeneration, pancreatic tumour and glioma, involving the administration of an effective amount of 3-[(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinolinyl)]-2-nonyl-2-propenoic acid (E3330) or its pharmaceutically acceptable salts or solvates. The decreased EHF-1α, NFKβ, AP-1 activity by E3330 and the suppression thereby of the growth, survival. Migration and metastasis of tumour cells are accompanied by the absence of the major suppression of the growth of normal cells (hemopoietic embyo cells or CD34+ human progenitors). Besides, E3330 has enhanced the therapeutic effect of other cytotoxic preparations.
EFFECT: reducing the amount of VGEF and proliferation of retinal endothelial cells by E333O even in the presence of a fibroblast growth factor, both in the normal oxygen conditions, and in the hypoxia by the inhibition of the oxidation-reduction activity of Apel/Ref-1.
12 cl, 35 dwg
SUBSTANCE: invention refers to medicine, namely to eye drops, and aims at treating dry eye syndrome, as well as bacterial conjunctivitis and/or blepharitis. The preparation comprises a combination of the ingredients, a prolonging ingredient, additives and water. The combination of the active ingredients contains branched polyhexamethylene guanidine and sulphacetamide; the prolonging ingredient is specified in a group consisting of polyvinyl alcohol, water-soluble methyl cellulose or hydroxypropyl methyl cellulose; the additives are specified in a group consisting of a group consisting of physiologically acceptable alkaline or acid agents, and a saline tonic agent.
EFFECT: using the invention enables higher clinical effectiveness of dry eye syndrome, as well as a comorbid bacterial infection, as the preparation possesses the bactericidal effect consistent with the effect of 20% sulphacetamide causing no irritant effect on long use.
4 cl, 3 tbl, 6 ex
SUBSTANCE: invention relates to medicine, namely ophthalmology. The method involves a transepithelial corneal collagen crosslinking. That is preceded with a single bath electrophoresis with 1% riboflavin mononucleotide. That is ensured by an initial current of 0.2 mA to be increased gradually to 1 mA, at a pitch of 0.2 mA for 2 minutes. That is followed by an ultraviolet corneal exposure. The exposure is conducted at wave length 370 nm, power 3 mWt/cm2 and combined with instillation of a riboflavin solution. The solution contains 0.1% riboflavin mononucleotide and 20% dextran.
EFFECT: method provides more effective riboflavin delivery to the corneal stroma for one procedure providing the intraocular protection against ultraviolet light.
2 cl, 1 ex
SUBSTANCE: invention refers to medicine, ophthalmology. A method involves a sinus trabeculectomy, a local sclerectomy and a drug delivery to a posterior pole of eyeball following by a restorative treatment. The local sclerectomy is performed in an inferior-internal segment of the eye with a cross-section of the incision being semi-circular. The local sclerectomy uses Histochrom as a drug substance. The restorative treatment comprises subconjunctival drug injections in a combination with the exposure to a physical factor. Starting from the first postoperative day, Histochrom is injected into a sub-Tenon's space. There are 9 injections performed once a day. Starting from the second postoperative day, a magnetic stimulation is used at frequency 100 Hz, length 16 minutes once a day for 7-10 days. The first 3 sessions involve the exposure to a pulsating monopolar magnetic field of intensity 6.25 mT. The following 4-7 sessions involve the exposure to an alternating bipolar magnetic field of intensity 12.5 mT.
EFFECT: method provides stabilising and enhancing the visual functions.
5 cl, 1 dwg, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to ophthalmic preparations presented in the form of eye drops and applicable for treating dry eye syndrome and bacterial conjunctivitis. The preparation contains polyhexamethylene guanidine that is presented by branched oligomers in the form of hydrochloride; besides, phosphate buffered saline, poly(N-vinylpyrrolidone) and water are the ingredients.
EFFECT: using the invention provides the higher clinical effectiveness in dry eye syndrome, as well as potential comorbid bacterial infection whereas the declared preparation has no irritant effect if used for a long period of time.
3 cl, 2 tbl, 3 ex
SUBSTANCE: invention refers to medicine, particularly ophthalmology, and may be used for treating inflammatory and dystrophic eye diseases. If observing an anterior segment of an eyeball, therapeutic agents are administered subcutaneously into a temporal region 1.8-2.2 cm above the middle of a cheek bone into a lymphatic capillary accumulation. If observing a posterior segment of the eyeball, the therapeutic agents are administered subcutaneously 0.8-1.2 cm below the top of a mastoid bone, as well as into the lymphatic capillary accumulation. Heparin in a single dose of 0.3 to 0.6 ml with the therapeutic substance concentration of 96% to 100% is initially administered into the above regions. The basic substance solution in a single dose of 0.6 to 0.8 ml with the therapeutic substance concentration of 45% to 55% is administered thereafter. That is followed by administering Contrykal in a single dose of 0.4 to 0.6 ml with the substance concentration of 45% to 55%. The manipulations are daily for 7-10 days with the therapeutic course repeated every 1-6 months.
EFFECT: method provides better trophism and microcirculation of an optic disk and retina, lower intensity of pathological reactions with obtaining the therapeutic substance concentrations faster, reducing injuries of the manipulation and doses of the administered preparations.
SUBSTANCE: invention relates to medicine, particularly to ophthalmology. That is ensured by the integrated treatment involving the single macular exposure to a sublimit micro-pulse infrared laser light. That is combined with the ozone therapy using drug preparations with underlying mixed gas agitation. That is followed by an antioxidant therapy consisting of local instillations of emixipin and oral administration of complivit oftalmo.
EFFECT: method enables the therapy of predisciform age-related macular degeneration at the stage of confluent drusens, preventing the development of the disease and improving the visual acuity.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to ophthalmology, and aims at treating a wide range of inflammatory ophthalmic diseases: bacterial, allergic, infectious allergic: conjunctivitis, blepharitis, keratitis and others. The eye drops contain a sulphanyl amide preparation, dexamethasone and water. The sulphanyl amide preparation is presented by sodium sulphacyl sodium. Additionally, the drops contain boric acid and hydroxypropyl methyl cellulose in the following proportions, wt %: sodium sulphacyl 8.0-12.0; dexamethasone 0.1-0.01; boric acid 0.4-0.6; hydroxypropyl methyl cellulose 0.4-0.6; water - the rest.
EFFECT: using the invention enables higher therapeutic effectiveness of using the declared eye drops ensured by their prolonged action by prolonging a corneal contact of the preparation.
SUBSTANCE: invention relates to medicine, namely to therapy and pulmonology, and can be used for selection of tactics of treating thromboembolism of pulmonary artery. For this purpose computered tomography with bolus enhancement is performed to patient, areas of affection located more distally than thrombotic embolus are examined and number of respiratory movements per minute is taken into account. Presence of occluded vessel or vessels in examined areas is identified. Occlusion of segmental branch of pulmonary artery, located more distally than embolus, is assessed in one point irrespective of degree of vessel occlusion. Occlusion of each of lobar branches in case of affection of right middle lobar, left middle- and upper lobar branches of pulmonary artery is assessed in 2 points. Occlusion of upper lobar branch of pulmonary artery on the right, lower lobar branch of pulmonary artery on the left is assessed in 3 points. Occlusion of right lower lobar branch of pulmonary artery is assessed in 4 points. Occlusion of left main pulmonary artery is assessed in 7 points. Occlusion of right main pulmonary artery is assessed in 9 points. Occlusion of both main pulmonary arteries and/or pulmonary trunk is assessed in 17 points. After that, points are summed up. If the sum of points is from 1 to 6, anticoagulation therapy is performed with heparin. If the sum of points constitutes from 7 to 10 at rate of respiratory movements (RRM) lower than 18, another anticoagulation therapy is performed, at RRM more than 18 - thrombolytic therapy is performed. If the sum of points constitutes from 11 to 17, thrombolytic therapy is performed.
EFFECT: method provides possibility of operative objective assessment of degree of pulmonary bed affection and beginning of required therapy in due time.
5 dwg, 1 tbl, 4 ex
SUBSTANCE: invention refers to medicine, namely cardiology and concerns treating the patients with ST segment elevation acute myocardial infarction. That is ensured by the two-bolus intravenous administration of the thrombolytic preparation Fortelysine in a dose of 10 mg, and 30 minutes later in a dose of 5 mg.
EFFECT: presented mode of administration of Fortelysine provides the effective recovery of the antegrade coronary blood flow in the infarction-involved coronary artery in the patients with ST segment elevation acute myocardial infarction.
SUBSTANCE: treatment involves the paracervical introduction of a mixture containing klaforan 2 g, hemase 5000 units, 0.5% novocaine 20.0 ml, prednisolone 50.0 mg. The mixture is introduced once a day for 10 days.
EFFECT: effective treatment followed by recovery of hormonal and ovulatory ovarian function.
SUBSTANCE: invention relates to medicine, namely to ophthalmology, and deals with treatment of hemorrhages which occur, for instance, at the background of age-related macular degeneration with subretinal neovascularisation. For this purpose courses of treatment are carried out in sessions, each of courses includes carrying out mydriasis of affected eye, puncture of sclera to vitreous body and alternate introduction of medications. At the first session introduced is medication which inhibits factor of vessel growth (MIFVG), fibrinolytic medication (FM) and medication of expanding gas (MEG), for instance, sulfur hexafluoride. At the second session, in case of hemorrhage, the same medications are introduced. If there is no hemorrhage at the second and following sessions only MIFVG is introduced. Simultaneously with puncture of sclera paracentesis of cornea is performed through which drainage of moisture, normalising intraocular pressure, is carried out. MIFVG dose is calculated depending on degree of retina edema, FM and MEG doses are selected proportionally to hemorrhage value determined during fundus examination. Single MEG dose constitutes 0.05-0.35 ml. After sessions, at which MEG is introduced for 1-1.5 weeks control over resolution process is performed and it is recommended to patient to preserve "face down" head position until gas is resolved completely. 10-15 seconds after introduction of all included into particular treatment session medications, needle is removed, interval between sessions is selected equal from 3 weeks to 1.5 months.
EFFECT: method increases treatment quality due to elaboration of specific regimen of impact of said treatment methods, which ensures not only elimination of hemorrhage but also leads to elimination of it causes with minimisation of traumatic factors of treatment.
SUBSTANCE: invention refers to medicine, and can be used if extremity vein catheterisation is required for multiple intravenous introduction of drug solutions. That is ensured by vein catheterisation followed by change of an extremity position with respect to a patient's trunk so that an open pavilion of the catheter is arranged below a level of a patient's right atrium. An infrared imager is used to monitor an extremity surface condition within a projection of the catheter. If observing a region of local hyperthermia along the vein, its content is examined by ultrasound. A thrombus if any is sized up; tourniquets are applied below and above the region of local hyperthermia to complete sanguimotion cessation in the vein. Then, blood is taken from the vein to its devastation, and the volume of taken blood portion is measured that is followed by introduction of 2% lidocaine hydrochloride 0.5 ml and a thrombolytic solution at temperature +42°C in the volume necessary for complete vein filling. 3 minutes later, the whole liquid vein content is removed through the catheter, and the tourniquets are released, the vein content is examined by ultrasound. The presence of a thrombus requires another 3-minute tourniquet application with venous blood replacement by a local anaesthetic solution with a thrombolytic agent to stabilise thrombus size, then the catheter is removed, and the drugs are introduced by means of another catheter which is inserted in another extremity vein.
EFFECT: method allows higher safety and effectiveness of vein catheterisation due to early phlebitis detection and exact delivery of fibrinolytic agents to the thrombus to dissolve a "fresh" portion of the thrombus that allows reducing a risk of thromboembolism.
SUBSTANCE: invention relates to medicine, namely to transplantology, and can be used in realisation of donor organs preservation. For this purpose from the region of supposed explantation of donor organ, blood is evacuated with its further cooling, oxygenation and returning into bloodstream, providing perfusion of said region. After that, removal of donor organ is performed and during not less than two hours its extracorporal perfusion with prepared perfusion solution is carried out. Composition of perfusion solution includes not less than 25% of preserving solution "Kustodiol", not less than 20% of perfluorane, not less than 1.5 mln IU of streptokinase, not less than 50000 IU of heparin, not less than 300 mcg of prednisolone. After organ removal activated leukocytes are removed from contour of extracorporal apparatus perfusion by means of leukocyte filter, and temperature of perfusion solution is reduced to 5°C-12°C.
EFFECT: method makes it possible to ensure extension of donor pool as a result of possible use of ischemically affected donor organs due to restoration of energy and functional potential of cells, including as a result of application of perfusion solution of multi-directional action.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of biotechnology and deals with recombinant plasmid DNA, which contains sequence of gene of mature staphylokinase Staphylococcus aureus with replacement of codons K74, E75 and R77 with triplets, which code Ala, of strain Escherichia coli MZ09 and method of obtaining recombinant protein, which contains sequence of gene of mature staphylokinase with replacement of codons K74, E75 and R77 with Ala-coding triplets. Essence of method includes recombinant plasmid DNA, which codes sequence of gene of mature protein of staphylokinase from Staphylococcus aureus staphylokinase with replacement of codons K74, E75 and R77 with Ala-coding triplets, which has nucleotide sequence, given in dwg.1. Invention also includes strain Esherichia coli MZ09, producent of recombinant staphylokinase, with sequence, given in dwg.1, as well as method of its obtaining.
EFFECT: invention makes it possible to obtain staphylokinase protein which possesses high fibrinogenic activity, with output of recombinant protein to 20% from total amount.
3 cl, 2 dwg
SUBSTANCE: invention is related to medicine, namely to angiologia and may be used for local lysis of obstructing thrombus inside any vessel. Catheter is used with balloon, which is blown to complete obturation of vessel, and fibrinolytic agent is introduced under pressure into produced space, isolated from one side with catheter balloon and thrombus on the other side, until complete lysis of thrombus.
EFFECT: method makes it possible to increase efficiency of treatment due to creation of high concentration of fibrinolytic agent in the area of thrombus and action of pressure at thrombus, and also to achieve reduction in number of complications.
1 dwg, 1 tbl, 1 ex
SUBSTANCE: invention refers to ophthalmology and can be used in surgery of subretinal haemorrhages combined with age-specific macular dystrophy with subretinal neovascular membrane. The technique involves subtotal vitrectomy and removal of posterior hyaloid membrane. Bevacizumab and Ranibizumab are injected intravitreally. It is followed with intravitreal injection of tissue plasminogen activator and expanding gas while a patient is pronated.
EFFECT: method allows deploying blood from under retina, ensuring pathogenetic action on haemorrhage source, preventing proliferative processes in vitreal cavity.
SUBSTANCE: polypeptides include single-domain antibody against vWF, A1 domain of vWF, A1 domain of activated vWF, A3 domain of vWF, gp1b and/or collagen. Invention claims methods of obtaining indicated polypeptides, methods of coating devices applied in medical practice (e.g. in X-ray structural analysis, endoprosthetics) with indicated polypeptides.
EFFECT: obtainment of polypeptides for treatment of diseases requiring modulation of thrombocyte-mediated aggregation.
40 cl, 69 ex, 30 dwg, 32 tbl
SUBSTANCE: invention refers to medicine, specifically to cardiology and concerns treating the patients suffering chronic cardiac failure. The method involves administering pharmacologically active relaxin H2 in a therapeutically effective amount equal to 10-480 mcg/kg a day. An indication for adding relaxin to the conducted therapy is chronic and stable compensated congestive cardiac failure at the moment of the beginning of treatment.
EFFECT: method provides reducing a rate of decompensation, a rate or length of stay in hospital, a risk of as compared to no-relaxin treatment.
6 cl, 2 ex, 3 tbl, 13 dwg